Cancer Research for the Ozarks (CRO) will continue its fifteen years of service to the regional community by providing access to clinical oncology research in prevention, control and treatment trials (phase II and phase III). The primary service area is the Springfield-Branson corridor, the third largest metro area in Missouri. CRO's affiliates in Joplin, Rolla and the satellite in West Plains extend access to those cities and a wide rural area. In 2002, the CRO hospitals and affiliates had approximately 5,000 new cancer cases. CRO is dedicated to expanding access to clinical trials by making a wide array of protocols available to its patient population from the maximum allowed number of research bases. Currently, CRO offers nearly one hundred and forty active protocols. CRO is also applying to add the Gynecology Oncology Group as its 6th research base. CRO continues to develop and implement strategies to increase minority participation including establishing long-term relationships with minority based organizations. CRO has been able to conduct targeted outreach to minorities as a result of these efforts. CRO has also identified opportunities to increase accrual to prevention and control trials. The CRO prevention trials committee partners with community organizations, local hospitals and physicians to offer broad-based cancer screening. CRO will expand these efforts to additional communities, establish annual outreach events and strengthen relationships with underserved populations. St. John's Regional Health Center and CoxHealth, the two health systems in Springfield and Co-Sponsors of the CRO - CCOP continue to expand their oncology services enhancing CRO's ability to recruit study participants. They have increased the number of oncologists on staff and are in the process of adding IMRT to their radiation centers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J1))
Program Officer
Kelaghan, Joseph
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ozark Health Ventures, LLC
United States
Zip Code
Ahmed, Amina; Deng, Wei; Tew, William et al. (2018) Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol 150:300-305
Aghajanian, Carol; Filiaci, Virginia; Dizon, Don S et al. (2018) A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol 150:274-281
Flaig, Thomas W; Plets, Melissa; Hussain, Maha H A et al. (2017) Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol 3:e170231
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8

Showing the most recent 10 out of 157 publications